Next Article in Journal
Transfusion-Associated Graft-Versus-Host Disease: A Concise Review
Previous Article in Journal
Essential Thrombocythemia, Hemolytic Anemia and Hepatic Cirrhosis: Could There Be an Association?
 
 
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Immunosuppression-Associated Posterior Reversible Encephalopathy Syndrome in an Acute Leukemia Case

Department of Hematology, Hacettepe University School of Medicine, TR-06100 Ankara, Turkey
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2018, 10(4), 7257; https://doi.org/10.4081/hr.2018.7257
Submission received: 10 June 2017 / Revised: 29 April 2018 / Accepted: 2 May 2018 / Published: 6 November 2018

Abstract

Posterior reversible encephalopathy syndrome (PRES) was described in 1996. Herein, we aimed to report an immunosuppression- related PRES case. A 34-year-old woman was diagnosed as t-cell acute lymphoblastic leukemia and allogeneic hematopoietic stem cell transplantation (HSCT) was performed. Cyclosporine was given for GVHD prophylaxis in addition to the other routine medications of HSCT. She was hospitalized for acute renal failure and due to the possible contribution of acute renal failure cyclosporine was stopped. Tacrolimus was started for GVHD prophylaxis at a dose of 1 mg/day. However, fifteen days after the initiation of tacrolimus, blurred vision occurred in our patient. Petechial bleeding sites were detected in bilateral cerebral and cerebellar hemisphere by MR imaging. Tacrolimus dosage was reduced to 0.5 mg/day. She had hypertension which was difficult to control and followed-up in the intensive care unit. She had seizures. Control cranial MR resulted as diffusion limitation in bilateral cerebellar hemisphere, bilateral occipital and frontal-parietal regions with vasogenic edema findings; contrast involvement in left frontal-parietal and right cerebellar regions. She had vision loss and lethargy. Control cranial MR favored PRES syndrome secondary to immunosuppression. Hypertensive state was taken under control with antihypertensive treatment and all immunosuppressive agents were stopped. Two weeks later her clinical condition was slightly improved. MR test which was conducted 2 weeks after the diagnosis revealed the regression of PRES lesions. The characteristic signs on neuroimaging are the symmetrical white matter edema in the posterior cerebral hemispheres, particularly the parietal- occipital regions. In conclusion, PRES rarely develops secondary to the immunosuppressive agents and the clinicians should suspect and promptly diagnose PRES which might cause otherwise serious irreversible clinical complications.
Keywords: posterior reversible encephalopathy syndrome; immunosuppression; leukemia posterior reversible encephalopathy syndrome; immunosuppression; leukemia

Share and Cite

MDPI and ACS Style

Malkan, U.Y.; Gunes, G.; Demiroglu, H.; Goker, H. Immunosuppression-Associated Posterior Reversible Encephalopathy Syndrome in an Acute Leukemia Case. Hematol. Rep. 2018, 10, 7257. https://doi.org/10.4081/hr.2018.7257

AMA Style

Malkan UY, Gunes G, Demiroglu H, Goker H. Immunosuppression-Associated Posterior Reversible Encephalopathy Syndrome in an Acute Leukemia Case. Hematology Reports. 2018; 10(4):7257. https://doi.org/10.4081/hr.2018.7257

Chicago/Turabian Style

Malkan, Umit Y., Gursel Gunes, Haluk Demiroglu, and Hakan Goker. 2018. "Immunosuppression-Associated Posterior Reversible Encephalopathy Syndrome in an Acute Leukemia Case" Hematology Reports 10, no. 4: 7257. https://doi.org/10.4081/hr.2018.7257

Article Metrics

Back to TopTop